Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXFP3 | Q9NSD7 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699459 | 0.83 | MAPT (0.49) | MAPTRXFP3KDM4EALOX12NPSR1 | |
| SCHEMBL914992 | 0.81 | MAPT (0.54) | MAPTKDM4EALOX12NPSR1MEN1 | |
| SCHEMBL4697826 | 0.81 | MAPT (0.54) | MAPTKDM4EALOX12NPSR1MEN1 | |
| SCHEMBL4697716 | 0.79 | MAPT (0.52) | MAPTKDM4EMEN1KMT2APOLB | |
| SCHEMBL4701725 | 0.78 | KMT2A (0.53) | MAPTKDM4EMEN1KMT2APOLB | |
| SCHEMBL4698010 | 0.78 | KMT2A (0.53) | MAPTKDM4EMEN1KMT2APOLB | |
| SCHEMBL530029 | 0.78 | MAPT (0.55) | MAPTKDM4EALOX12NPSR1MEN1 | |
| SCHEMBL529833 | 0.78 | MAPT (0.55) | MAPTKDM4EALOX12NPSR1MEN1 | |
| Acetic Acid SCHEMBL915011 | 0.75 | MAPT (0.56) | MAPTKDM4EMEN1KMT2APOLB | |
| Acetic Acid SCHEMBL915013 | 0.75 | MAPT (0.56) | MAPTKDM4EMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309544-B1 | COMPOUNDS ACTING AS MELANOCORTIN RECEPTOR LIGANDS | ACURE PHARMA AB (SE) | 2008-11-05 | — | — | EP | claimed |
| US-7153881-B2 | Compounds acting as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2006-12-26 | — | — | US | claimed |
| EP-1309544-B1 | COMPOUNDS ACTING AS MELANOCORTIN RECEPTOR LIGANDS | ACURE PHARMA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-7153881-B2 | Compounds acting as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20040019094-A1 | Compounds acting as melanocortin receptor ligands | HPF IP HOLDING S.A. (LU) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019094-A1 | Compounds acting as melanocortin receptor ligands | MC1R, MC3R, MC5R | MAPT 3667/4885RXFP3 202/4885KDM4E 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.